Events and Presentations Events and Presentations Upcoming Events There are no upcoming events available at this time. Past Events September 15, 2020 at 9:20 AM EDT Cantor Virtual Global Healthcare Conference Click here for webcast August 12, 2020 at 2:30 PM EDT Stoke Therapeutics at Canaccord Genuity 40th Annual Growth Conference Click here for webcast August 11, 2020 at 2:00 PM EDT Stoke Therapeutics at BTIG Virtual Biotechnology Conference Click here for webcast August 11, 2020 at 11:30 AM EDT Stoke Therapeutics at 2020 Wedbush PacGrow Healthcare Virtual Conference Click here for webcast June 12, 2020 Stoke Therapeutics at Association for Research in Vision & Ophthalmology Meeting 2020 Supporting Materials Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy 3.7 MB Corporate Presentation Corporate Presentation – August 2020 Key Publications August 26, 2020 Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome Source Science Translational Medicine July 9, 2020 Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression Source Nature Communications Genetic Epilepsies Presentations AES2019 cyno pharmacology poster AES2019 mouse efficacy poster Ophthalmology Presentations Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy Poster: Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for treatment of autosomal dominant optic atrophy Toolkit Print Page Email Alerts Contact IR FAQ
Events and Presentations Upcoming Events There are no upcoming events available at this time. Past Events September 15, 2020 at 9:20 AM EDT Cantor Virtual Global Healthcare Conference Click here for webcast August 12, 2020 at 2:30 PM EDT Stoke Therapeutics at Canaccord Genuity 40th Annual Growth Conference Click here for webcast August 11, 2020 at 2:00 PM EDT Stoke Therapeutics at BTIG Virtual Biotechnology Conference Click here for webcast August 11, 2020 at 11:30 AM EDT Stoke Therapeutics at 2020 Wedbush PacGrow Healthcare Virtual Conference Click here for webcast June 12, 2020 Stoke Therapeutics at Association for Research in Vision & Ophthalmology Meeting 2020 Supporting Materials Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy 3.7 MB Corporate Presentation Corporate Presentation – August 2020 Key Publications August 26, 2020 Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome Source Science Translational Medicine July 9, 2020 Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression Source Nature Communications Genetic Epilepsies Presentations AES2019 cyno pharmacology poster AES2019 mouse efficacy poster Ophthalmology Presentations Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy Poster: Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for treatment of autosomal dominant optic atrophy
August 12, 2020 at 2:30 PM EDT Stoke Therapeutics at Canaccord Genuity 40th Annual Growth Conference Click here for webcast
August 11, 2020 at 2:00 PM EDT Stoke Therapeutics at BTIG Virtual Biotechnology Conference Click here for webcast
August 11, 2020 at 11:30 AM EDT Stoke Therapeutics at 2020 Wedbush PacGrow Healthcare Virtual Conference Click here for webcast
June 12, 2020 Stoke Therapeutics at Association for Research in Vision & Ophthalmology Meeting 2020 Supporting Materials Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy 3.7 MB
Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy 3.7 MB
August 26, 2020 Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome Source Science Translational Medicine
July 9, 2020 Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression Source Nature Communications
Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy
Poster: Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for treatment of autosomal dominant optic atrophy